Bianchi Lab
@TheBianchiLab
Followers
541
Following
554
Media
3
Statuses
380
Physician-Scientist running a hypothesis-driven research program to develop effective therapies for Amyloidosis and Myeloma patients. @brighamheme @harvardmed
Boston, MA
Joined September 2021
Congrats Sri!!!.
We congratulate Srinivas Viswanathan, MD, PhD, a 2025 AACR-@KidneyCAN Kidney Cancer Innovation and Discovery Grant recipient. We look forward to his work on TFE3 fusion inhibitors for translocation renal cell carcinoma, a rare kidney cancer with no approved targeted therapies.
0
0
3
Thanks @Transplant_Doc ! We are excited to make this highly effective treatment option available to AL amyloidosis patients through a prospective clinical trial @DanaFarber, shortly opening at other centers in the US. #amyloidosis.
Elranatamab elicits deep and rapid heme responses in patients with RR AL amyloidosis without any new AEs, even in patients with advanced heart failure #mmsm #amyloid @rajshekharucms @TheBianchiLab @BloodPortfolio @SLentzsch
1
2
8
Thanks @rajshekharucms. What an amazing option for our patients with AL amyloidosis! More to come from our multicenter, prospective study of elra for relapsed/refractory disease @DanaFarber. #amyloidosis.
In another multicenter (@columbiacancer and @BrighamWomens) study of BCMA BsAb in AL Amyloidosis (including stage IIIb), brisk and deep hematologic responses translating into organ responses, despite short follow-up! Now we need:.Prospective data.Long term follow up to test.
0
1
6
Thanks @Myeloma_Doc ! It was great to collaborate with @rajshekharucms and @SLentzsch for this initial report of clinical activity of elranatamab in patients with AL amyloidosis. Our prospective study of Elra in relapsed/refractory disease is rapidly accruing at @DanaFarber.
#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: #mmsm
0
1
4
RT @Francesco_Bia: I could not be more proud! @DomenicoGiannon, the king of nowcasting and simply a superb econometrician, has just joined….
0
8
0
RT @matteoclaudio84: Thrilled to share our new work out today on @BloodPortfolio #Blood where we described the role of pPCs in the TME of P….
0
3
0
Way to go @MMoscvin ! Congratulations and so well deserved.
Honored to have been selected for the Young Investigator Scholarship for the SOHO 2025! Hope to see new and old friends in Houston! Thank you @SurbhiSidanaMD for the support and mentorship. @SocietyofHemOnc . #SOHO2025
0
0
2
Thanks @MMoscvin. And another paper for you, rising star in plasma cell dyscrasia:) you were there from the beginning!.
@TheBianchiLab is always an inspiration for how to go beyond your comfort zone in science and medicine!!.
0
1
4
A labor of love! Excited to see this online first. #amyloidosis. It was a treat to collaborate with many friends: @KleinLabHMS, Ray Comenzo, Mario Nuvolone, @nickbolli, Joao Paulo @GygiLab. Thanks @BloodPortfolio!
ashpublications.org
Key Points. AL amyloidosis patients show changes in malignant plasma cell (PCs) and enrichment in a newly defined, normal PC subset.An inflammatory transcr
0
4
23
RT @ASH_hematology: ASH is committing more than $12 million to address research funding challenges and support the next generation of hemat….
0
31
0
RT @Francesco_Bia: Congratulations to the @BOK_newsletter for hosting the 20th edition its International Conference and many thanks for hav….
0
1
0
RT @ricco_giovanni: Thank you to @Francesco_Bia and all participants for creating with us another great “Advances in Structural Shocks Iden….
0
8
0
Could not agree more @rajshekharucms ! I share same concerns around short and long term side effects of CAR-T as compared to BiTE. Length of response in amyloidosis is also key. Hope to share early data about our prospective elra trial in amyloidosis at ASH! Going strong!.
Impressive efficacy data from NEXICART-2 in AL #Amyloidosis at #ASCO25! Few thoughts: .1. With low plasma cell burden in relapsed/refractory AL, I do expect ~90-100% MRD-negative heme-CR rate with BCMA CAR T (The 3 VGPR/low-dFLC PRs will deepen into heme-CR with a bit more.
0
0
5
Disappointed by negative outcome of birtamimab. Many patients enrolled at our center in the hope of effect. Hopefully correlative studies will shed some light. We will continue to push forward for novel effective therapies for patients with #amyloidosis.
Breaking News: @ProthenaCorp has announced that the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with Mayo Stage IV AL #amyloidosis failed to meet its primary endpoint. Learn more:
0
1
6
Disappointed to be notified of negative outcome of birtamimab. Many patients enrolled at our center in the hope of effect. Hopefully correlative studies will shed some light. We will continue to push forward for novel effective therapies for patients with #amyloidosis.
Breaking News: @ProthenaCorp has announced that the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with Mayo Stage IV AL #amyloidosis failed to meet its primary endpoint. Learn more:
0
0
11
RT @Myeloma_Doc: #Myeloma Paper of the Day: Panel on cardiac #amyloidosis in older adults concludes frailty is dynamic & modifiable; interv….
0
5
0
Congrats @SagarLonialMD ! Well deserved!.
Congratulations to Dr. @SagarLonialMD for receiving the JEAN-LUC HAROUSSEAU AWARD @COMyCongress @WinshipAtEmory @EmoryUniversity
0
2
16
RT @DrDamluji: Cardiac Amyloidosis in Older Adults With a Focus on Frailty: JACC: Advances Expert Consensus: @JACCJournals . 🥸 @DrAROrkaby….
0
37
0